Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Positive results presented from second phase III psoriasis study of bimekizumab

Nov. 18, 2019

Long, low growth factor signaling promotes healing

Nov. 12, 2019

First-in-human comparison of LY-2775240 and apremilast in healthy volunteers

Nov. 11, 2019

Phase IIb ATLAS study of etokimab fails to meet the primary endpoint

Nov. 11, 2019

Hoth Therapeutics initiates confirmatory study of the AEA-loaded-Z pods in models of lupus

Nov. 7, 2019

Further interim data presented from phase Ib study of EDP-1815 in patients with psoriasis

Nov. 6, 2019

Clinical development of MOR-106 for atopic dermatitis ended for futility

Oct. 29, 2019

BioCryst Pharmaceuticals discloses complement factor D inhibitors

Oct. 29, 2019

Microbion announces phase Ib data for pravibismane in infected diabetic foot ulcers

Oct. 29, 2019

First subject dosed in phase II ADVISE study of etrasimod in atopic dermatitis

Oct. 29, 2019

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...